Versteegh MM - Search Results

1

Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.

Arnold DT, Rowen D, Versteegh MM, Morley A, Hooper CE, Maskell NA. Arnold DT, et al. Among authors: versteegh mm. Health Qual Life Outcomes. 2015 Jan 23;13:6. doi: 10.1186/s12955-014-0196-y. Health Qual Life Outcomes. 2015. PMID: 25613110 Free PMC article.

2

Mapping onto Eq-5 D for patients in poor health.

Versteegh MM, Rowen D, Brazier JE, Stolk EA. Versteegh MM, et al. Health Qual Life Outcomes. 2010 Nov 26;8:141. doi: 10.1186/1477-7525-8-141. Health Qual Life Outcomes. 2010. PMID: 21110838 Free PMC article.

3

Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.

Versteegh MM, Leunis A, Luime JJ, Boggild M, Uyl-de Groot CA, Stolk EA. Versteegh MM, et al. Med Decis Making. 2012 Jul-Aug;32(4):554-68. doi: 10.1177/0272989X11427761. Epub 2011 Nov 22. Med Decis Making. 2012. PMID: 22114301

4

Condition-specific preference-based measures: benefit or burden?

Versteegh MM, Leunis A, Uyl-de Groot CA, Stolk EA. Versteegh MM, et al. Value Health. 2012 May;15(3):504-13. doi: 10.1016/j.jval.2011.12.003. Epub 2012 Feb 9. Value Health. 2012. PMID: 22583461 Free article.

5

An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences.

Crott R, Versteegh M, Uyl-de-Groot C. Crott R, et al. Qual Life Res. 2013 Jun;22(5):1045-54. doi: 10.1007/s11136-012-0220-9. Epub 2012 Jun 29. Qual Life Res. 2013. PMID: 22743734

6

Time to tweak the TTO: results from a comparison of alternative specifications of the TTO.

Versteegh MM, Attema AE, Oppe M, Devlin NJ, Stolk EA. Versteegh MM, et al. Eur J Health Econ. 2013 Jul;14 Suppl 1(Suppl 1):S43-51. doi: 10.1007/s10198-013-0507-y. Eur J Health Econ. 2013. PMID: 23900664 Free PMC article.

7

Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis.

Versteegh M. Versteegh M. Pharmacoeconomics. 2016 Nov;34(11):1133-1144. doi: 10.1007/s40273-016-0421-0. Pharmacoeconomics. 2016. PMID: 27282692 Free PMC article.

8

Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma.

de Groot S, Redekop WK, Versteegh MM, Sleijfer S, Oosterwijk E, Kiemeney LALM, Uyl-de Groot CA. de Groot S, et al. Among authors: versteegh mm. Qual Life Res. 2018 Jan;27(1):115-124. doi: 10.1007/s11136-017-1704-4. Epub 2017 Sep 15. Qual Life Res. 2018. PMID: 28917029 Free PMC article.

9

Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool.

Gheorghe M, Hoefman RJ, Versteegh MM, van Exel J. Gheorghe M, et al. Among authors: versteegh mm. Pharmacoeconomics. 2019 Jan;37(1):93-103. doi: 10.1007/s40273-018-0706-6. Pharmacoeconomics. 2019. PMID: 30151734 Free PMC article.

10

Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.

Franken MD, de Hond A, Degeling K, Punt CJA, Koopman M, Uyl-de Groot CA, Versteegh MM, van Oijen MGH. Franken MD, et al. Among authors: versteegh mm. Health Qual Life Outcomes. 2020 Jul 20;18(1):240. doi: 10.1186/s12955-020-01481-2. Health Qual Life Outcomes. 2020. PMID: 32690011 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters